1887
Volume 2026, Issue 1
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Neoadjuvant chemotherapy (NACT) is used in breast cancer (BC) to downsize and downstage the tumor before surgery. Different studies were conducted looking into the alterations in the immunohistochemistry after NACT, which may alter the adjuvant treatment. Our study aimed to assess the changes in immunohistochemistry biomarker status (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) in BC cells after administration of NACT at a single institution in Oman.

We conducted a retrospective cross-sectional study on patients with BC with residual disease post-NACT in a single institution and studied immunohistochemistry status changes before and after NACT. We used the McNemar test to evaluate the receptor changes, and logistic regression to assess the effect of risk factors on receptor status change.

All biomarkers changed after NACT, with a tendency for BC cells to lose PR and HER2 expression and gain ER expression. The immunohistochemistry changes were 36/114 (31.6%) in PR, 7/114 (6.1%) in ER, and 11/114 (9.6%) in HER2. BC subtypes changed in 4/114 (3.5%) of HER2+ve, 10/114 (8.8%) of hormone positive (ER or PR) with HER2 overexpression (HER2+ve/HR+ve), 3/114 (2.6%) in hormone positive with HER2 negative (HR+ve), and 3/114 (2.6%) triple-negative BCs. These changes resulted in adjuvant treatment adjustments in 9/110 (8.18%) patients with residual disease.

Changes in the expression of all immunohistochemistry biomarkers and BC subtypes occurred after NACT, which led to changes in adjuvant treatment in specific cases.

© 2026 Al-Ani, Al Ismaili, Al-Mahrouqi N, Al-Sayegh, Al Baimani, Ali Alshahi, et al.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2026.3
2026-03-03
2026-03-03

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2026/1/qmj.2026.3.html?itemId=/content/journals/10.5339/qmj.2026.3&mimeType=html&fmt=ahah

References

  1. Al-Sayegh H, Al-Zadjali S, Al-Moundhri M. Analyzing cancer incidence trends in Oman from 1996 to 2019: a comprehensive study of the National Cancer Annual Reports. JCO Glob Oncol. 2024 Feb; 10:e2300337. https://doi.org/10.1200/GO.23.00337
     [Google Scholar]
  2. Al-Lawati N, Al-Siyabi N, Al-Wehaibi S. Cancer Incidence in Oman 2020. Department of Non-Communicable Diseases Directorate General of Primary Health Care. 2023 Dec. Available from: https://moh.gov.om/media/qqkfk1u4/cancer-incidence-in-oman-2020.pdf [cited Apr 1, 2025].
     [Google Scholar]
  3. Al Hinai F, Al Qassabi B. National Early Detection & Screening for Breast Cancer Guideline. Department of Woman and Child Health, Ministry of Health, Sultanate of Oman. 2025;(Second Edition):47. Available from: https://moh.gov.om/media/g0bewvct/early-detection-breast-cancer-screening-guidelines.pdf [cited Apr 1, 2025].
     [Google Scholar]
  4. Kumar S, Burney IA, Al-Ajmi A, Al-Moundhri MS. Changing trends of breast cancer survival in Sultanate of Oman. J Oncol. 2011; 2011:316243. https://doi.org/10.1155/2011/316243
     [Google Scholar]
  5. Kaufmann M, Von minckwitz G, Bear HD, Buzdar A, Mcgale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007 Dec; 18:(12):1927–34. https://doi.org/10.1093/annonc/mdm201
     [Google Scholar]
  6. Masood S. Neoadjuvant chemotherapy in breast cancers. Womens Health (Lond). 2016 Sep; 12:(5): 480–91. https://doi.org/10.1177/1745505716677139
     [Google Scholar]
  7. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17:(2):460–9. https://doi.org/10.1200/JCO.1999.17.2.460
     [Google Scholar]
  8. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol. 2001 Aug; 28:(4):389–99. https://doi.org/10.1016/s0093-7754(01)90132-0
     [Google Scholar]
  9. van der Hage JA, van de Velde CJH, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 2001 Nov; 19:(22):4224–37. https://doi.org/10.1200/JCO.2001.19.22.4224
     [Google Scholar]
  10. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 2002 Apr; 86:(7):1041–6. https://doi.org/10.1038/sj.bjc.6600210
     [Google Scholar]
  11. Shaaban AM, Provenzano E. Receptor status after neoadjuvant therapy of breast cancer: significance and implications. Pathobiology. 2022; 89:(5):297–308. https://doi.org/10.1159/000521880
     [Google Scholar]
  12. National Comprehensive Cancer Network . Breast Cancer Version 3.2025. 2025. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
     [Google Scholar]
  13. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24:(9):2206–23. https://doi.org/10.1093/annonc/mdt303
     [Google Scholar]
  14. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017 Mar; 67:(2):93–9. https://doi.org/10.3322/caac.21388
     [Google Scholar]
  15. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, Mcshane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023 Aug; 41:(22):3867–72. https://doi.org/10.1200/JCO.22.02864
     [Google Scholar]
  16. Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023 Sep; 41:(27):4433–42. https://doi.org/10.1200/JCO.23.00435
     [Google Scholar]
  17. Mimori K, Saito T, Niida A, Miyano S. Cancer evolution and heterogeneity. Ann Gastroenterol Surg. 2018 Jul; 2:(5):332–8. https://doi.org/10.1002/ags3.12182
     [Google Scholar]
  18. Fumagalli C, Barberis M. Breast cancer heterogeneity. Diagnostics (Basel). 2021 Aug; 11:(9):1555. https://doi.org/10.3390/diagnostics11091555
     [Google Scholar]
  19. Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, et al. A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med. 2021 Aug; 9:(16):1351. https://doi.org/10.21037/atm-21-1948
     [Google Scholar]
  20. Candás G, García A, Ocampo MD, Korbenfeld E, Vuoto HD, Isetta J, et al. Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer. Ecancermedicalscience. 2021 Jan; 15:1162. https://doi.org/10.3332/ecancer.2021.1162
     [Google Scholar]
  21. Jaime Dos Santos B, Balabram D, Mara Reis Gomes V, de Castro C, Henrique Costa Diniz P, Araújo Buzelin M, et al. Changes in invasive breast carcinomas after neoadjuvant chemotherapy can influence adjuvant therapeutic decisions. Cancer Res Treat. 2024 Jan; 56:(1):178–90. https://doi.org/10.4143/crt.2023.386
     [Google Scholar]
  22. Al-Saleh K, Salah T, Arafah M, Husain S, Al-Rikabi A, El-Aziz NA. Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: results from a tertiary Cancer Center in Saudi Arabia. PLoS One. 2021 Mar; 16:(3):e0247802. https://doi.org/10.1371/journal.pone.0247802
     [Google Scholar]
  23. Gahlaut R, Bennett A, Fatayer H, Dall BJ, Sharma N, Velikova G, et al. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - implications for the practising oncologist. Eur J Cancer. 2016 Jun; 60:40–8. https://doi.org/10.1016/j.ejca.2016.03.006
     [Google Scholar]
  24. Coiro S, Gasparini E, Falco G, Santandrea G, Foroni M, Besutti G, et al. Biomarkers changes after neoadjuvant chemotherapy in breast cancer: a seven-year single institution experience. Diagnostics (Basel). 2021 Dec; 11:(12):Diagnostics (Basel). https://doi.org/10.3390/diagnostics11122249
     [Google Scholar]
  25. Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011 Nov; 29:(9):594–8. https://doi.org/10.3109/07357907.2011.621913
     [Google Scholar]
  26. Lim SK, Lee MH, Park IH, You JY, Nam BH, Kim BN, et al. Impact of molecular subtype conversion of breast cancers after neoadjuvant chemotherapy on clinical outcome. Cancer Res Treat. 2016 Jan; 48:(1):133–41. https://doi.org/10.4143/crt.2014.262
     [Google Scholar]
/content/journals/10.5339/qmj.2026.3
Loading
The impact of neoadjuvant chemotherapy on immunohistochemistry and molecular subtype in breast cancer: A retrospective analysis from Oman
Qatar Medical Journal 2026, 3 (2026); https://doi.org/10.5339/qmj.2026.3
/content/journals/10.5339/qmj.2026.3
/content/journals/10.5339/qmj.2026.3
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): breast neoplasms, ErbB-2 receptors, Estrogen receptors, Neoadjuvant therapy and Progesterone receptors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error